Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
| Brand name | DULOXETINE |
| Generic name | DULOXETINE HYDROCHLORIDE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Breckenridge Pharmaceutical, Inc. |
| NDC | 51991-748-90 |
| Full product label | Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain; Dist. by: Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ 07922. |
| Recalling firm | Breckenridge Pharmaceutical, Inc. |
| Distribution | U.S. Nationwide |
| Quantity | 172,263 bottles |
| Recall initiated | 2025-10-09 |
| Report date | 2025-11-05 |
| Recall completed | — |
| Recall number | D-0100-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Berkeley Heights NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗